AMGN – Amgen Inc.
Float Short %
2.49
Margin Of Safety %
9
Put/Call OI Ratio
0.91
EPS Next Q Diff
-0.58
EPS Last/This Y
13.62
EPS This/Next Y
0.62
Price
321.23
Target Price
330.79
Analyst Recom
2.3
Performance Q
14.74
Relative Volume
1.33
Beta
0.45
Ticker: AMGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | AMGN | 323.66 | 0.73 | 0.63 | 130959 |
| 2025-11-11 | AMGN | 338.4 | 0.73 | 0.33 | 137252 |
| 2025-11-12 | AMGN | 336.32 | 0.73 | 0.36 | 146149 |
| 2025-11-13 | AMGN | 335.99 | 0.74 | 0.31 | 150396 |
| 2025-11-14 | AMGN | 336.89 | 0.72 | 0.96 | 157479 |
| 2025-11-17 | AMGN | 341.71 | 0.74 | 0.93 | 147725 |
| 2025-11-18 | AMGN | 344.38 | 0.72 | 0.39 | 152438 |
| 2025-11-19 | AMGN | 342.53 | 0.73 | 0.66 | 154685 |
| 2025-11-20 | AMGN | 336.02 | 0.74 | 0.07 | 159237 |
| 2025-11-21 | AMGN | 337.49 | 0.99 | 0.75 | 143943 |
| 2025-11-24 | AMGN | 334.08 | 0.92 | 0.58 | 133834 |
| 2025-11-25 | AMGN | 340.85 | 0.90 | 0.81 | 139240 |
| 2025-11-26 | AMGN | 344.57 | 0.90 | 0.94 | 141424 |
| 2025-12-01 | AMGN | 337.67 | 0.94 | 0.70 | 143858 |
| 2025-12-02 | AMGN | 338.39 | 0.95 | 1.24 | 153876 |
| 2025-12-03 | AMGN | 345.42 | 0.95 | 0.97 | 156622 |
| 2025-12-04 | AMGN | 340.15 | 0.92 | 0.23 | 162138 |
| 2025-12-05 | AMGN | 329.41 | 0.89 | 0.46 | 167125 |
| 2025-12-08 | AMGN | 321.31 | 0.91 | 1.36 | 158037 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | AMGN | 323.66 | -7.6 | 4621.4 | 21.04 |
| 2025-11-11 | AMGN | 338.45 | -7.6 | 5339.5 | 21.22 |
| 2025-11-12 | AMGN | 336.28 | -7.6 | 4682.4 | 21.22 |
| 2025-11-13 | AMGN | 335.92 | -9.0 | 4804.3 | 21.23 |
| 2025-11-14 | AMGN | 336.87 | -9.0 | 4850.9 | 21.23 |
| 2025-11-17 | AMGN | 341.80 | -9.3 | 5009.4 | 21.24 |
| 2025-11-18 | AMGN | 343.92 | -10.2 | 4900.7 | 21.23 |
| 2025-11-19 | AMGN | 342.40 | -10.2 | 4759.0 | 21.23 |
| 2025-11-20 | AMGN | 335.96 | -10.2 | 4577.7 | 21.23 |
| 2025-11-21 | AMGN | 337.51 | -10.5 | 4872.5 | 21.23 |
| 2025-11-24 | AMGN | 334.34 | -10.5 | 4794.4 | 21.23 |
| 2025-11-25 | AMGN | 341.11 | -10.8 | 5176.8 | 21.24 |
| 2025-11-26 | AMGN | 344.49 | -10.8 | 5043.3 | 21.24 |
| 2025-12-01 | AMGN | 337.54 | -10.8 | 4691.3 | 21.24 |
| 2025-12-02 | AMGN | 338.36 | -10.8 | 5021.1 | 21.24 |
| 2025-12-03 | AMGN | 345.42 | -10.8 | 5256.7 | 21.24 |
| 2025-12-04 | AMGN | 340.15 | -10.8 | 4790.6 | 21.24 |
| 2025-12-05 | AMGN | 329.89 | -10.8 | 4598.4 | 21.24 |
| 2025-12-08 | AMGN | 321.23 | -10.8 | - | 21.24 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | AMGN | -0.24 | -0.48 | 2.14 |
| 2025-11-11 | AMGN | -0.24 | -0.48 | 2.14 |
| 2025-11-12 | AMGN | -0.24 | -0.48 | 2.50 |
| 2025-11-13 | AMGN | -0.24 | -0.48 | 2.50 |
| 2025-11-14 | AMGN | -0.92 | -0.48 | 2.50 |
| 2025-11-17 | AMGN | -0.92 | 0.08 | 2.50 |
| 2025-11-18 | AMGN | -0.92 | 0.08 | 2.50 |
| 2025-11-19 | AMGN | -0.92 | 0.08 | 2.50 |
| 2025-11-20 | AMGN | -0.92 | 0.08 | 2.50 |
| 2025-11-21 | AMGN | -0.92 | 0.08 | 2.50 |
| 2025-11-24 | AMGN | -1.19 | -0.49 | 2.50 |
| 2025-11-25 | AMGN | -1.32 | -0.49 | 2.50 |
| 2025-11-26 | AMGN | -1.32 | -0.49 | 2.49 |
| 2025-12-01 | AMGN | -1.32 | -0.56 | 2.49 |
| 2025-12-02 | AMGN | -1.32 | -0.56 | 2.49 |
| 2025-12-03 | AMGN | -1.32 | -0.56 | 2.49 |
| 2025-12-04 | AMGN | -1.32 | -0.56 | 2.49 |
| 2025-12-05 | AMGN | -1.32 | -0.56 | 2.49 |
| 2025-12-08 | AMGN | -1.18 | -0.47 | 2.49 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
5.64
Avg. EPS Est. Current Quarter
4.74
Avg. EPS Est. Next Quarter
5.06
Insider Transactions
-1.18
Institutional Transactions
-0.47
Beta
0.45
Average Sales Estimate Current Quarter
9457
Average Sales Estimate Next Quarter
8656
Fair Value
350.16
Quality Score
86
Growth Score
87
Sentiment Score
31
Actual DrawDown %
7.4
Max Drawdown 5-Year %
-24.9
Target Price
330.79
P/E
24.83
Forward P/E
14.66
PEG
5.28
P/S
4.82
P/B
17.98
P/Free Cash Flow
14.99
EPS
12.94
Average EPS Est. Cur. Y
21.24
EPS Next Y. (Est.)
21.86
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
19.52
Relative Volume
1.33
Return on Equity vs Sector %
45.9
Return on Equity vs Industry %
36.5
EPS 1 7Days Diff
EPS 1 30Days Diff
0.2
EBIT Estimation
Amgen Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 28000
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
stock quote shares AMGN – Amgen Inc. Stock Price stock today
news today AMGN – Amgen Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AMGN – Amgen Inc. yahoo finance google finance
stock history AMGN – Amgen Inc. invest stock market
stock prices AMGN premarket after hours
ticker AMGN fair value insiders trading